别名 COCKAYNE SYNDROME A、COCKAYNE SYNDROME B、CSA + [81] |
简介 A syndrome characterized by multiple system abnormalities including DWARFISM; PHOTOSENSITIVITY DISORDERS; PREMATURE AGING; and HEARING LOSS. It is caused by mutations of a number of autosomal recessive genes encoding proteins that involve transcriptional-coupled DNA REPAIR processes. Cockayne syndrome is classified by the severity and age of onset. Type I (classical; CSA) is early childhood onset in the second year of life; type II (congenital; CSB) is early onset at birth with severe symptoms; type III (xeroderma pigmentosum; XP) is late childhood onset with mild symptoms. |
靶点 |
作用机制 C5抑制剂 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2018-12-21 |
靶点- |
作用机制- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期1964-06-08 |
靶点- |
作用机制 细胞替代物 |
在研机构 Immunecyte, Inc.初创企业 |
原研机构 Immunecyte, Inc.初创企业 |
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2023-05-01 |
申办/合作机构 |
开始日期2023-04-06 |
申办/合作机构- |
开始日期2023-04-06 |